Darifenacin - In the treatment of overactive bladder

Darifenacin is a selective muscarinic, M-3-receptor antagonist that has been evaluated in clinical trials in patients with overactive bladder syndrome (OAB) using a controlled-release formulation. A In multicentre, randomised, double-blind trials in patients with OAB, darifenacin 7.5 or 15mg once daily for 12 weeks significantly reduced the frequency of urinary incontinence, frequency of micturition and frequency and severity of urgency versus placebo. A significant difference from placebo was apparent 2 weeks after starting treatment. At a dosage of 30mg once daily, darifenacin significantly prolonged warning time compared with placebo. A Darifenacin 15mg once daily for 2 weeks was as effective as oxybutynin 5mg three times daily at reducing the frequency of urinary incontinence and frequency and severity of urgency in patients with OAB. A Darifenacin was generally well tolerated in clinical trials. The most common adverse events were dry mouth and constipation. CNS tolerability appeared to be similar to that of placebo. A Darifenacin had no adverse effect on cognitive function in healthy elderly volunteers.